188 East Blaine Street, Suite 400
Seattle, WA 98102
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a team of 200 plus scientists, engineers, clinicians and biotechnology veterans creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
11 articles with Sana Biotechnology
Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.
Biopharma companies raking in the cash with investment rounds and IPO announcements.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors.
1/8/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Sana Biotechnology Builds Key Regulatory Capabilities as Ke Liu, M.D., Ph.D., Joins Senior Leadership Team
Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Ke Liu , M.D., Ph.D., has joined the senior leadership team as Sana's Head of Regulatory Affairs & Strategy.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
On October 30, the company announced the acquisition of long-time collaborator Oscine Corp.
Sana will leverage Oscine's technologies to develop stem cell derived therapies for CNS disorders Steve Goldman, M.D., Ph.D., joins Sana as the Head of CNS Therapy
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D.
Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. Ed Rebar , Ph.D., joins the company as Chief Technology Officer and Terry Fry , M.D. joins as SVP, Head of T Cell Therapeutics.